Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in low-risk and INT-1 MDS with iron overload
NCT00117507Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Adverse Events and Serious Adverse Events at 52 weeks. Started Sep 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT00117507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117507.